GLP-1 Drugs... Are They Destroying Muscle? — What Semaglutide, Tirzepatide & Retatrutide Data Actually Shows

A clinical deep dive into the muscle loss problem on GLP-1 medications. Semaglutide, tirzepatide, and the investigational triple agonist retatrutide all produce remarkable weight loss — but clinical trial data shows that a significant fraction of that loss is lean body mass, not fat. This episode covers the mechanism behind GLP-1-induced muscle wasting, the body composition data from STEP 1 and SURMOUNT trials, who carries the highest risk, and where the next generation of obesity pharmacology — bimagrumab combinations, pemvidutide, and retatrutide's glucagon receptor pathway — is trying to solve the problem. For clinicians, patients, and anyone paying attention to where obesity medicine is actually going.This podcast is for informational purposes only and is not medical advice.